Suppr超能文献

在“所有人”研究计划参与者中,与体重变化相关的药物使用情况。

Use of medications associated with weight change among participants in the All of Us research programme.

机构信息

Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Department of Health Policy & Management, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.

出版信息

Clin Obes. 2023 Oct;13(5):e12609. doi: 10.1111/cob.12609. Epub 2023 Jul 16.

Abstract

Our objective was to describe the use of medications associated with weight change among US adults with overweight/obesity, including anti-obesity medications (AOMs), weight-loss-promoting and weight-gain-promoting medications. We performed a cross-sectional analysis of data from the nationwide All of Us Research Programme. We included adults with measured body mass index (BMI) ≥ 27 kg/m enrolled between 2018 and 2022 across the United States. We used linked electronic health record data to determine medication use ±12 months of BMI measure. Our 132 057 participants had mean age 54 years and mean BMI 34 kg/m ; 60% of participants were women, 62% White, and 32% Black. Only 1% used any AOM, and 14% used at least one weight-loss-promoting medication. We found that 36% used at least one weight-gain-promoting medication, and approximately 20% used multiple weight-gain-promoting medications. While AOMs are underutilized by participants with overweight/obesity, weight-gain-promoting medication use is common. Our results raise concern about potential iatrogenic weight gain from medications. Future research is needed to estimate the long-term effect of weight-gain-promoting medications on weight status and determine whether weight-loss benefits occur with their discontinuation. Clinician education on AOMs and weight-loss-promoting medications may be needed to increase their use.

摘要

我们的目标是描述美国超重/肥胖成年人中与体重变化相关的药物使用情况,包括抗肥胖药物(AOM)、促进体重减轻和促进体重增加的药物。我们对全美所有人研究计划的数据进行了横断面分析。我们纳入了 2018 年至 2022 年期间在美国测量的身体质量指数(BMI)≥27kg/m²的成年人。我们使用关联的电子健康记录数据来确定 BMI 测量±12 个月内的药物使用情况。我们的 132057 名参与者的平均年龄为 54 岁,平均 BMI 为 34kg/m²;60%的参与者为女性,62%为白人,32%为黑人。只有 1%的人使用任何 AOM,14%的人使用至少一种促进体重减轻的药物。我们发现,36%的人使用至少一种促进体重增加的药物,约 20%的人使用多种促进体重增加的药物。虽然超重/肥胖患者对 AOM 的使用不足,但促进体重增加的药物使用很常见。我们的结果引起了对药物引起潜在医源性体重增加的关注。需要进一步研究来估计促进体重增加的药物对体重状况的长期影响,并确定停止使用这些药物是否会带来减肥益处。可能需要对 AOM 和促进体重减轻的药物进行临床医生教育,以增加其使用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d8c/10528729/663f18a89cbd/nihms-1915405-f0001.jpg

相似文献

3
8
Obesity Management in Adults: A Review.成人肥胖管理:综述。
JAMA. 2023 Nov 28;330(20):2000-2015. doi: 10.1001/jama.2023.19897.
10
Real-world primary nonadherence to antiobesity medications.真实世界中抗肥胖药物的原发性用药不依从。
J Manag Care Spec Pharm. 2023 Oct;29(10):1099-1108. doi: 10.18553/jmcp.2023.23083. Epub 2023 Aug 18.

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验